In the past week, SNDX stock has gone down by -8.02%, with a monthly gain of 5.88% and a quarterly surge of 2.16%. The volatility ratio for the week is 3.06%, and the volatility levels for the last 30 days are 4.43% for Syndax Pharmaceuticals Inc The simple moving average for the last 20 days is -5.55% for SNDX’s stock, with a simple moving average of 7.42% for the last 200 days.
Is It Worth Investing in Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Right Now?
Moreover, the 36-month beta value for SNDX is 0.93. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SNDX is 80.06M and currently, short sellers hold a 10.65% of that float. On July 29, 2024, SNDX’s average trading volume was 1.05M shares.
SNDX) stock’s latest price update
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) has experienced a decline in its stock price by -12.15 compared to its previous closing price of 24.49. However, the company has seen a fall of -8.02% in its stock price over the last five trading days. prnewswire.com reported 2024-07-29 that – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass., July 29, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for revumenib for the treatment of adults and pediatric patients with relapsed or refractory (R/R) KMT2Ar acute leukemia.
Analysts’ Opinion of SNDX
Many brokerage firms have already submitted their reports for SNDX stocks, with Jefferies repeating the rating for SNDX by listing it as a “Buy.” The predicted price for SNDX in the upcoming period, according to Jefferies is $37 based on the research report published on June 28, 2024 of the current year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see SNDX reach a price target of $23, previously predicting the price at $36. The rating they have provided for SNDX stocks is “Sector Perform” according to the report published on January 31st, 2024.
Mizuho gave a rating of “Buy” to SNDX, setting the target price at $45 in the report published on December 22nd of the previous year.
SNDX Trading at 2.13% from the 50-Day Moving Average
After a stumble in the market that brought SNDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.09% of loss for the given period.
Volatility was left at 4.43%, however, over the last 30 days, the volatility rate increased by 3.06%, as shares surge +4.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.46% lower at present.
During the last 5 trading sessions, SNDX fell by -8.51%, which changed the moving average for the period of 200-days by +69.17% in comparison to the 20-day moving average, which settled at $22.82. In addition, Syndax Pharmaceuticals Inc saw -0.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNDX starting from Goldan Keith A., who purchase 1,250 shares at the price of $20.03 back on Jun 14 ’24. After this action, Goldan Keith A. now owns 52,623 shares of Syndax Pharmaceuticals Inc, valued at $25,037 using the latest closing price.
Morrison Briggs, the Director of Syndax Pharmaceuticals Inc, sale 52,855 shares at $18.27 during a trade that took place back on Aug 09 ’23, which means that Morrison Briggs is holding 17,836 shares at $965,402 based on the most recent closing price.
Stock Fundamentals for SNDX
Current profitability levels for the company are sitting at:
- -491.51 for the present operating margin
- 0.21 for the gross margin
The net margin for Syndax Pharmaceuticals Inc stands at -448.94. The total capital return value is set at -0.54. Equity return is now at value -51.89, with -47.99 for asset returns.
Based on Syndax Pharmaceuticals Inc (SNDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -147.64. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -3174.12.
Currently, EBITDA for the company is -229.94 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 3218.37. The receivables turnover for the company is 0.07for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.93.
Conclusion
To wrap up, the performance of Syndax Pharmaceuticals Inc (SNDX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
